Sutro Biopharma, Inc. (STRO)
Nasdaq · Healthcare · Biotechnology
$15.13−1.43%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $251M
- 52-week range
- $7.15 – $43.85
- 52-week change
- +76.44%
- EPS (trailing)
- −$17.28
- Analyst rating
- 1.4 Strong buy
Fiscal year to Dec 2025
- Revenue
- $102M (+65.18%)
- Net income
- −$191M
- Operating margin
- −154.5%
- Diluted EPS
- −$22.49
From the company’s annual report on SEC EDGAR.
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc.
Headquarters: South San Francisco, United States · 128 employees · sutrobio.com